Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7286MR)

This product GTTS-WQ7286MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7286MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8843MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ4103MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ4372MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ15744MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ7270MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ3206MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ12883MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ15499MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7665
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW